KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.

Xiaohua Wu, Yang Sun, Hongying Yang, Jing Wang, Hanmei Lou, Dan Li, Ke Wang, Hui Zhang, Tao Wu, Yuzhi Li, Chunyan Wang, Guiling Li, Yifeng Wang, Dapeng Li, Ying Tang, Mei Pan, Hongyi Cai, Weihu Wang, Bing Yang, Hua Qian, Qiuhong Tian, Desheng Yao, Ying Cheng, Bing Wei, Xiumin Li, Tao Wang, Min Hao, Xiaohong Wang, Tiejun Wang, Juntao Ran, Hong Zhu, Lijing Zhu, Xianling Liu, Yunxia Li, Lihong Chen, Qingshan Li, Xiaojian Yan, Fei Wang, Hongbing Cai, Yunyan Zhang, Zhiqing Liang, Funan Liu, Yi Huang, Bairong Xia, Pengpeng Qu, Genhai Zhu, Youguo Chen, Kun Song, Meili Sun, Zhengzheng Chen, Qiang Zhou, Lina Hu, Guzhalinuer Abulizi, Hongyan Guo, Sihai Liao, Yijing Ye, Ping Yan, Qiu Tang, Guoping Sun, Ting Liu, Dongmei Lu, Mingxiu Hu, Zhongmin M Wang, Baiyong Li, Michelle Xia

Lancet 404(10463) 1668-1676

PMID39426385
PMCID-
DOI10.1016/S0140-6736(24)02135-4
发表日期2024-10-19
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: Cadonilimab is a bispecific antibody targeting PD-1 and CTLA-4, which has shown substantial clinical benefits in advanced cervical cancer. In the COMPASSION-16 trial, we aimed to evaluate the addition of cadonilimab to first-line standard chemotherapy in persistent, recurrent, or metastatic cervical cancer. METHODS: In this randomised, double-blind, multicentre, placebo-controlled phase 3 trial, women aged 18-75 years across 59 clinical sites in China with previously untreated persistent, recurrent, or metastatic cervical cancer were randomly assigned (1:1) to receive cadonilimab (10 mg/kg) or placebo plus platinum-based chemotherapy with or without bevacizumab every 3 weeks for six cycles, followed by maintenance therapy every 3 weeks for up to 2 years. Randomisation was performed centrally through an interactive web-response system. Stratification factors were the use of bevacizumab (yes or no) and previous concurrent chemoradiotherapy (yes or no). The dual primary outcomes were progression-free survival as assessed by blinded independent central review and overall survival in the full analysis set. This study is registered with ClinicalTrials.gov, NCT04982237; the study has completed enrolment and is ongoing for treatment and follow-up. FINDINGS: 445 eligible women were enrolled between Sept 11, 2021, and June 23, 2022. Median progression-free survival was 12·7 months (95% CI 11·6-16·1) in the cadonilimab group and 8·1 months (7·7-9·6) in the placebo group (hazard ratio 0·62 [95% CI 0·49-0·80], p<0·0001); median overall survival was not reached (27·0 months to not estimable) versus 22·8 months (17·6-29·0), respectively (hazard ratio 0·64 [0·48-0·86], p=0·0011). The most common grade 3 or higher adverse events were decreased neutrophil count, decreased white blood cell count, and anaemia. INTERPRETATION: The addition of cadonilimab to first-line standard chemotherapy significantly improved progression-free survival and overall survival with a manageable safety profile in participants with persistent, recurrent, or metastatic cervical cancer. The data support the use of cadonilimab plus chemotherapy as an efficacious first-line therapy in persistent, recurrent, or metastatic cervical cancer. FUNDING: Akeso Biopharma.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。